Turnstone Biologics Corp. (TSBX)
(Delayed Data from NSDQ)
$0.70 USD
+0.01 (1.15%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.69 -0.01 (-1.71%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Turnstone Biologics Corp falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 95 | 82 | 161 | -99,999 | -99,999 |
Receivables | 0 | 9 | 7 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 7 | 7 | 9 | NA | NA |
Total Current Assets | 103 | 98 | 177 | NA | NA |
Net Property & Equipment | 6 | 10 | 7 | NA | NA |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | NA |
Deposits & Other Assets | 1 | 3 | 1 | NA | NA |
Total Assets | 113 | 115 | 187 | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 0 | 3 | 0 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 10 | 14 | 21 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 0 | 15 | 33 | NA | NA |
Total Current Liabilities | 12 | 35 | 55 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 4 | 39 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 1 | 2 | 1 | NA | NA |
Minority Interest (Liabilities) | 0 | 172 | 172 | NA | NA |
Total Liabilities | 14 | 216 | 269 | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | NA |
Common Stock (Par) | 0 | 0 | 0 | NA | NA |
Capital Surplus | 276 | 21 | 9 | NA | NA |
Retained Earnings | -177 | -122 | -91 | NA | NA |
Other Equity | 0 | 0 | 0 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 99 | -101 | -82 | NA | NA |
Total Liabilities & Shareholder's Equity | 113 | 115 | 187 | NA | NA |
Total Common Equity | 99 | -101 | -82 | 0 | 0 |
Shares Outstanding | 23.00 | NA | NA | NA | NA |
Book Value Per Share | 4.29 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Turnstone Biologics Corp falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 63 | 78 | 95 | 109 | 49 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 7 | 7 | 9 | 7 |
Total Current Assets | 68 | 85 | 103 | 119 | 56 |
Net Property & Equipment | 6 | 6 | 6 | 8 | 9 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 6 |
Total Assets | 77 | 94 | 113 | 131 | 75 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 0 | 2 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 9 | 10 | 9 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 16 | 13 | 12 | 13 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 3 | 3 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 172 |
Total Liabilities | 17 | 14 | 14 | 17 | 195 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 278 | 277 | 276 | 274 | 23 |
Retained Earnings | -218 | -196 | -177 | -160 | -143 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 60 | 80 | 99 | 114 | -121 |
Total Liabilities & Shareholder's Equity | 77 | 94 | 113 | 131 | 75 |
Total Common Equity | 60 | 80 | 99 | 114 | -121 |
Shares Outstanding | 23.10 | 23.10 | 23.00 | 22.80 | 22.10 |
Book Value Per Share | 2.59 | 3.46 | 4.29 | 5.00 | -5.46 |